Is Energy Transfer a Good Dividend Stock to Buy Now?
Energy Transfer (NYSE:ET) offers an impressive yield, to say the…
Sell
8
SOPH Quote, Financials, Valuation and Earnings
Last price:
$2.90
Seasonality move
:
-21.67%
Day range:
$2.89 - $2.99
52-week range:
$2.60 - $6.28
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.92x
P/B ratio:
1.99x
Volume:
26K
Avg. volume:
42.2K
1-year change:
-42.4%
Market cap:
$192.5M
Revenue:
$65.2M
EPS (TTM):
-$0.95
Analysts' Opinion
-
Consensus RatingSophia Genetics SA has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.80, Sophia Genetics SA has an estimated upside of 136.11% from its current price of $2.88.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $2.88.
Fair Value
-
According to the consensus of 5 analysts, Sophia Genetics SA has 136.11% upside to fair value with a price target of $6.80 per share.
SOPH vs. S&P 500
-
Over the past 5 trading days, Sophia Genetics SA has underperformed the S&P 500 by -1.28% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Sophia Genetics SA does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sophia Genetics SA has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Sophia Genetics SA reported revenues of $17.7M.
Earnings Growth
-
Sophia Genetics SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Sophia Genetics SA reported earnings per share of -$0.23.
Enterprise value:
125.5M
EV / Invested capital:
--
Price / LTM sales:
2.92x
EV / EBIT:
--
EV / Revenue:
1.93x
PEG ratio (5yr expected):
-1.52x
EV / Free cash flow:
-2.46x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$43.9M
Return On Assets:
-34.7%
Net Income Margin (TTM):
-95.89%
Return On Equity:
-50.8%
Return On Invested Capital:
-47.72%
Operating Margin:
-98.37%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $47.6M | $62.4M | $65.2M | $17M | $17.7M | |
| Gross Profit | $31.3M | $42.9M | $43.9M | $11.9M | $12.1M | |
| Operating Income | -$87.8M | -$74.8M | -$66.6M | -$18.9M | -$17.4M | |
| EBITDA | -$81.4M | -$69.6M | -$50.8M | -$20M | -$7.9M | |
| Diluted EPS | -$1.37 | -$1.22 | -$0.95 | -$0.37 | -$0.23 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $109.7M | $282.9M | $196.3M | $148M | $99.4M | |
| Total Assets | $132.1M | $320.2M | $243.8M | $206.2M | $155.3M | |
| Current Liabilities | $21.6M | $28.6M | $26.8M | $35.6M | $26.8M | |
| Total Liabilities | $31.6M | $44.8M | $43.7M | $54.7M | $58.8M | |
| Total Equity | $100.5M | $275.4M | $200.1M | $151.4M | $96.5M | |
| Total Debt | $3.3M | -- | -- | -- | $13.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$70.1M | -$48.6M | -$42.8M | -$11.3M | -$10.6M | |
| Cash From Investing | $42M | $8.3M | -$8.2M | -$2.2M | -$1.9M | |
| Cash From Financing | -$1.6M | -$2.8M | $11.6M | -$506K | -$573K | |
| Free Cash Flow | -$80.5M | -$57.8M | -$51M | -$13.5M | -$12.5M | |
SOPH
Sector
Market Cap
$192.5M
$33.9M
Price % of 52-Week High
45.86%
41.2%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.91%
1-Year Price Total Return
-42.4%
-46.15%
Beta (5-Year)
--
0.743
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.88
200-day SMA
Sell
Level
$3.65
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$3.09
Relative Strength Index (RSI14)
Sell
Level
43.91
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-75.6522
50-day SMA
Sell
Level
$3.43
MACD (12, 26)
Sell
Level
-0.16
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.161)
Sell
CA Score
(Annual)
Level (-0.951)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (2.64)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Stock Forecast FAQ
In the current month, SOPH has received 4 Buy ratings 1 Hold ratings, and 0 Sell ratings. The SOPH average analyst price target in the past 3 months is $6.80.
-
Where Will Sophia Genetics SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sophia Genetics SA share price will rise to $6.80 per share over the next 12 months.
-
What Do Analysts Say About Sophia Genetics SA?
Analysts are divided on their view about Sophia Genetics SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sophia Genetics SA is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Sophia Genetics SA's Price Target?
The price target for Sophia Genetics SA over the next 1-year time period is forecast to be $6.80 according to 5 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is SOPH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sophia Genetics SA is a Buy. 4 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SOPH?
You can purchase shares of Sophia Genetics SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sophia Genetics SA shares.
-
What Is The Sophia Genetics SA Share Price Today?
Sophia Genetics SA was last trading at $2.90 per share. This represents the most recent stock quote for Sophia Genetics SA. Yesterday, Sophia Genetics SA closed at $2.88 per share.
-
How To Buy Sophia Genetics SA Stock Online?
In order to purchase Sophia Genetics SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Did the Market Bottom Already?
The past few weeks have been among the most volatile…
Will NVIDIA Return to Its 52-Week High?
NVIDIA (NASDAQ:NVDA) has been among the best-performing investments of the…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
50
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
52
RGC alert for Apr 14
Regencell Bioscience Holdings [RGC] is down 11.8% over the past day.
Buy
52
SLP alert for Apr 14
Simulations Plus [SLP] is up 4.69% over the past day.
Sell
38
ZLAB alert for Apr 14
Zai Lab [ZLAB] is up 6.77% over the past day.
